Clearmind Medicine gains U.S. patent on binge behavior

Clearmind Medicine Inc. reports that it has been granted U.S. Patent No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS,” by the United States Patent and Trademark Office.

Rhea-AI Filing Summary

Clearmind Medicine Inc. reports that it has been granted U.S. Patent No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS,” by the United States Patent and Trademark Office. The patent covers compositions and methods using the company’s MEAI (5-methoxy-2-aminoindane) molecule to regulate binge behaviors such as excessive drinking, eating, and gambling.

The company states that this patent expands its global intellectual property portfolio to 32 granted patents across nineteen patent families and supports its clinical programs targeting binge-related disorders, including alcohol use disorder, and its lead candidate CMND-100. Clearmind focuses on non-hallucinogenic, second generation neuroplastogen-derived therapeutics for central nervous system conditions.

Insights

Biotech IP analyst

Clearmind adds a targeted U.S. patent around MEAI for binge behaviors.

Clearmind Medicine has obtained U.S. Patent No. 12,350,242 covering MEAI-based compositions and methods aimed at regulating binge behaviors, including excessive drinking, eating, and gambling. Management links this protection to its programs in binge-related disorders such as alcohol use disorder.

The company notes this raises its portfolio to 32 granted patents across nineteen patent families, reinforcing an IP-heavy strategy around non-hallucinogenic neuroplastogen-derived CNS therapies like CMND-100. Stronger patent coverage can help defend potential future products, though commercial outcomes will depend on clinical and regulatory progress described in other filings.

The first two paragraphs of this press release are incorporated by reference into multiple Clearmind shelf and incentive plan registration statements, aligning disclosure about MEAI and binge behavior regulators with existing capital markets documentation. Subsequent SEC filings are expected to provide more detail on clinical and business developments.

Key Figures

U.S. patent number: No. 12,350,242 Granted patents: 32 granted patents Patent families: Nineteen patent families

3 metrics

U.S. patent number No. 12,350,242 Patent titled “BINGE BEHAVIOR REGULATORS” granted by USPTO

Granted patents 32 granted patents Total granted patents in Clearmind’s portfolio after new U.S. patent

Patent families Nineteen patent families Size of Clearmind’s overall intellectual property portfolio

Key Terms

neuroplastogens, binge behaviors, alcohol use disorder, intellectual property portfolio, +1 more

5 terms

neuroplastogens medical

"non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems"

Neuroplastogens are drugs or molecules designed to boost the brain’s ability to reorganize and form new connections—think of them as medicines that help the brain ‘rewire’ itself after damage or during therapy. Investors watch them because successful neuroplastogens could become treatments for conditions like depression, Alzheimer’s, or brain injury, creating large markets and sharp changes in company value as trials, approvals, or setbacks occur.

binge behaviors medical

"to regulate binge behaviors, including excessive drinking, eating, and gambling"

alcohol use disorder medical

"binge-related disorders, such as alcohol use disorder, where patients urgently need more effective options"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

intellectual property portfolio financial

"expanding its robust intellectual property portfolio"

A collection of a company’s legally recognized creations and rights—such as patents, trademarks, copyrights, trade secrets and licensing agreements—that together protect its products, brands and technologies. Think of it as the company’s toolbox or recipe box: some items keep competitors out, some can be rented or sold, and some enable unique products. For investors, the breadth and strength of this portfolio affect future revenue potential, competitive position and legal risk, so it influences valuation and investment decisions.

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind Medicine (CMND) announce in this Form 6-K?

Clearmind Medicine announced it has been granted U.S. Patent No. 12,350,242 titled “BINGE BEHAVIOR REGULATORS.” The patent covers MEAI-based compositions and methods targeting binge behaviors such as excessive drinking, eating, and gambling, strengthening its neuroplastogen-focused central nervous system pipeline.

What does Clearmind’s new U.S. patent cover for CMND?

The patent covers innovative compositions and methods using Clearmind’s MEAI (5-methoxy-2-aminoindane) molecule as a pharmaceutically acceptable salt to regulate binge behaviors. These include excessive drinking, eating, and gambling, aligning with the company’s focus on binge-related disorders like alcohol use disorder.

How large is Clearmind Medicine’s patent portfolio after this grant?

Clearmind states that its intellectual property portfolio now includes 32 granted patents across nineteen patent families. The company emphasizes ongoing efforts to seek additional patents and opportunistically acquire further IP to support its lead candidate CMND-100 and broader CNS therapeutic pipeline.

How does the new patent relate to Clearmind’s clinical programs?

Management believes the new U.S. patent directly advances its clinical programs for binge-related disorders, including alcohol use disorder. By protecting MEAI-based approaches to regulating binge behaviors, the patent is positioned as supporting the development and potential commercialization of CMND-100 and related CNS technologies.

What type of company is Clearmind Medicine (CMND)?

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on non-hallucinogenic, second generation neuroplastogen-derived therapeutics. It targets widespread, underserved conditions such as alcohol use disorder and aims to commercialize psychedelic-based compounds as regulated medicines, foods, or supplements under a patent-driven strategy.

How is this Clearmind press release used in SEC registrations?

The first two paragraphs of the press release are incorporated by reference into Clearmind’s Form F-3 and Form S-8 registration statements. This means the patent and binge behavior regulator information becomes part of those SEC filings from the submission date unless later superseded.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 08:11 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: June 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on June 18, 2026, titled “Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators”.

The first two paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: June 18, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

 

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

Vancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced that it has been granted a U.S. Patent, No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO).

The patent, which refers to Clearmind’s molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, including excessive drinking, eating, and gambling.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “We are very pleased to secure this important U.S. patent, increasing our global portfolio to 32 granted patents and reinforcing our leadership in psychedelic-based therapies. We believe that this milestone directly advances our clinical programs for binge-related disorders, such as alcohol use disorder, where patients urgently need more effective options. Clearmind remains committed to expanding its robust intellectual property portfolio. We continue to build broad IP protection in major global markets for our lead candidate, CMND-100, and our broader pipeline of central nervous system (CNS) therapeutic technologies."

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its leadership in psychedelic-based therapies, advancing its clinical programs for binge-related disorders and its commitment to expanding its robust intellectual property portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company.  Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "CLEARMIND MEDICINE GRANTED U.S. PATENT FOR BINGE BEHAVIOR 8.1 KB